EA201200560A1 - Специфическая терапия, использующая интегриновые лиганды для лечения рака - Google Patents
Специфическая терапия, использующая интегриновые лиганды для лечения ракаInfo
- Publication number
- EA201200560A1 EA201200560A1 EA201200560A EA201200560A EA201200560A1 EA 201200560 A1 EA201200560 A1 EA 201200560A1 EA 201200560 A EA201200560 A EA 201200560A EA 201200560 A EA201200560 A EA 201200560A EA 201200560 A1 EA201200560 A1 EA 201200560A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- ligands
- therapy
- integrine
- cancer treatment
- specific therapy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
Изобретение касается комбинированной терапии для лечения опухолей и опухолевых метастазов, включающей введение интегриновых лигандов, предпочтительно интегриновых антагонистов, вместе с котерапевтическими агентами или формами терапии, которые имеют синергистическую эффективность при последовательном введении с указанными лигандами, такими как химиотерапевтические агенты и/или лучевая терапия. Терапия приводит к синергистическому потенциальному увеличению эффекта ингибирования каждого индивидуального терапевтического средства на пролиферацию опухолевых клеток, приводя к более эффективному лечению, чем обнаружено при введении индивидуального компонента по отдельности, одновременно или не в режиме дозировки настоящего изобретения.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06000988 | 2006-01-18 | ||
EP06001044 | 2006-01-18 | ||
EP06006003 | 2006-01-20 | ||
EP06015883 | 2006-07-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201200560A1 true EA201200560A1 (ru) | 2012-09-28 |
Family
ID=38171155
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201200560A EA201200560A1 (ru) | 2006-01-18 | 2007-01-18 | Специфическая терапия, использующая интегриновые лиганды для лечения рака |
EA200801671A EA016817B1 (ru) | 2006-01-18 | 2007-01-18 | Специфическая терапия, использующая интегриновые лиганды для лечения рака |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA200801671A EA016817B1 (ru) | 2006-01-18 | 2007-01-18 | Специфическая терапия, использующая интегриновые лиганды для лечения рака |
Country Status (10)
Country | Link |
---|---|
US (1) | US20090130098A1 (ru) |
EP (3) | EP1973569B1 (ru) |
JP (2) | JP2009523813A (ru) |
KR (1) | KR20080089489A (ru) |
AU (1) | AU2007207465B2 (ru) |
BR (1) | BRPI0706540A2 (ru) |
CA (1) | CA2637387A1 (ru) |
EA (2) | EA201200560A1 (ru) |
ES (2) | ES2521679T3 (ru) |
WO (1) | WO2007084670A2 (ru) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008082537A2 (en) | 2006-12-19 | 2008-07-10 | The General Hospital Corporation | Compounds for modulating integrin cd11b/cd18 |
BRPI0806596A2 (pt) * | 2007-01-18 | 2013-07-23 | Merck Patent Ges Mit Berchraenkter Haftung | medicamento e terapia especÍfica usando-se ligantes de integrina para o tratamento de cÂncer |
CA2697070A1 (en) * | 2007-08-24 | 2009-03-05 | University Health Network | Methods of inhibiting tumor growth using beta 5 integrin antagonists |
JP2012509287A (ja) * | 2008-11-20 | 2012-04-19 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 癌を治療するためのインテグリンリガンドを用いる新規療法および医薬 |
KR20120116425A (ko) * | 2009-11-30 | 2012-10-22 | 프로테오로직스 엘티디 | 작은 피리미딘 유도체 및 이의 사용 방법 |
US9023876B2 (en) * | 2010-07-08 | 2015-05-05 | Adhaere Pharmaceuticals, Inc. | Compounds and methods for regulating integrins |
SG192667A1 (en) | 2011-02-11 | 2013-09-30 | Merck Patent Gmbh | Anti-alpha-v integrin antibody for the treatment of prostate cancer |
CA2856329A1 (en) | 2011-11-17 | 2013-05-23 | Nencki Institute Of Experimental Biology | Compositions and methods for treating glioma |
AU2013248972A1 (en) | 2012-04-20 | 2014-11-13 | Adhaere Pharmaceuticals, Inc. | Compounds and methods for regulating integrins |
US10960230B2 (en) | 2012-10-16 | 2021-03-30 | Nam P. Nguyen | Calibration of hypoxic region focused radiotherapy treatment plans |
US10166405B2 (en) * | 2012-10-16 | 2019-01-01 | Nam Nguyen | Image-guided radiotherapy for internal tumor boost |
US9895554B2 (en) | 2012-10-16 | 2018-02-20 | Nam Nguyen | Image-guided radiotherapy for internal tumor boost |
WO2016041614A1 (en) | 2014-09-17 | 2016-03-24 | Merck Patent Gmbh | A method of treating solid cancers and/or metastases thereof, medicaments therefore, and a method of predicting the clinical outcome of treating solid cancers and/or metastases thereof |
KR20170055540A (ko) | 2014-09-17 | 2017-05-19 | 메르크 파텐트 게엠베하 | 뼈 전이 질환 치료 방법, 그에 따른 약제, 및 뼈 전이 질환 치료의 임상 결과 예측 방법 |
RU2736045C2 (ru) | 2015-03-06 | 2020-11-11 | Бейондспринг Фармасьютикалс, Инк. | Способ лечения рака, ассоциированного с мутацией ras |
BR112017018964A2 (pt) * | 2015-03-06 | 2018-05-22 | Beyondspring Pharmaceuticals Inc | uso de plinabulin e métodos para tratar tumor cerebral |
KR20180027563A (ko) | 2015-07-13 | 2018-03-14 | 비욘드스프링 파마수티컬스, 인코포레이티드. | 플리나불린 조성물 |
SG11201806583XA (en) | 2016-02-08 | 2018-09-27 | Beyondspring Pharmaceuticals Inc | Compositions containing tucaresol or its analogs |
EP3207937A1 (en) | 2016-02-17 | 2017-08-23 | Royal College of Surgeons in Ireland | A method of treating or preventing sepsis |
WO2017182834A1 (en) * | 2016-04-19 | 2017-10-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | New method for treating resistant glioblastoma |
SG11201810872UA (en) | 2016-06-06 | 2019-01-30 | Beyondspring Pharmaceuticals Inc | Composition and method for reducing neutropenia |
JP2020503363A (ja) | 2017-01-06 | 2020-01-30 | ビヨンドスプリング ファーマシューティカルズ,インコーポレイテッド | チューブリン結合化合物およびその治療的使用 |
AU2018217120B2 (en) | 2017-02-01 | 2024-02-08 | Beyondspring Pharmaceuticals, Inc. | Method of reducing neutropenia |
RU2654417C1 (ru) * | 2017-05-29 | 2018-05-17 | Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр онкологии имени Н.Н. Петрова" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ им. Н.Н. Петрова" Минздрава России) | Способ расчёта дозы противоопухолевого препарата при выполнении нормотермической изолированной химиоперфузии лёгкого с метастазэктомией |
JP7350015B2 (ja) | 2018-01-24 | 2023-09-25 | ビヨンドスプリング ファーマシューティカルズ,インコーポレイテッド | プリナブリンの投与による血小板減少症を軽減するための組成物および方法 |
WO2019208820A1 (ja) * | 2018-04-27 | 2019-10-31 | 国立大学法人北海道大学 | 細胞内物質移送システムおよびその利用 |
MX2022000990A (es) * | 2019-08-02 | 2022-02-16 | Univ California | Composiciones y metodos que se dirigen y eliminan celulas madre cancerosas (csc) positivas para alfa-v beta-3 (av?3) y tratan canceres resistentes a farmacos y metastasicos. |
CA3208998A1 (en) | 2021-01-22 | 2022-07-28 | Steven Kerrigan | Treatment of coronavirus |
CN113289014B (zh) * | 2021-05-10 | 2022-05-17 | 上海交通大学 | 超小粒径的两性离子聚肽/没食子酸/铁配位纳米粒子及其制备方法与应用 |
Family Cites Families (84)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3396536A (en) * | 1966-08-08 | 1968-08-13 | Cessna Aircraft Co | Hydraulic transmission |
FR2268956B1 (ru) * | 1974-04-24 | 1977-06-24 | Messier Hispano Sa | |
US4342566A (en) | 1980-02-22 | 1982-08-03 | Scripps Clinic & Research Foundation | Solid phase anti-C3 assay for detection of immune complexes |
US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
US5260291A (en) | 1981-08-24 | 1993-11-09 | Cancer Research Campaign Technology Limited | Tetrazine derivatives |
US4661111A (en) | 1982-08-04 | 1987-04-28 | La Jolla Cancer Research Foundation | Polypeptide |
US4517686A (en) | 1982-08-04 | 1985-05-21 | La Jolla Cancer Research Foundation | Polypeptide |
US4578079A (en) | 1982-08-04 | 1986-03-25 | La Jolla Cancer Research Foundation | Tetrapeptide |
US4589881A (en) | 1982-08-04 | 1986-05-20 | La Jolla Cancer Research Foundation | Polypeptide |
US4792525A (en) | 1982-08-04 | 1988-12-20 | La Jolla Cancer Research Foundation | Tetrapeptide |
US4614517A (en) | 1982-08-04 | 1986-09-30 | La Jolla Cancer Research Foundation | Tetrapeptide |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4754603A (en) * | 1987-07-20 | 1988-07-05 | Rosman Allan H | Hydraulic-drive system for an intermittent-demand load |
DE69029036T2 (de) | 1989-06-29 | 1997-05-22 | Medarex Inc | Bispezifische reagenzien für die aids-therapie |
WO1991003493A1 (en) | 1989-08-29 | 1991-03-21 | The University Of Southampton | Bi-or trispecific (fab)3 or (fab)4 conjugates |
DK0553244T4 (da) | 1990-10-05 | 2005-08-01 | Celldex Therapeutics Inc | Målrettet immunostimulering med bispecifikke reagenser |
CA2097060A1 (en) | 1990-12-04 | 1992-06-05 | Peter J. Curtis | Bifunctional antibodies and method of preparing same |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
US5932448A (en) | 1991-11-29 | 1999-08-03 | Protein Design Labs., Inc. | Bispecific antibody heterodimers |
EP1997894B1 (en) | 1992-02-06 | 2011-03-30 | Novartis Vaccines and Diagnostics, Inc. | Biosynthetic binding protein for cancer marker |
US5407804A (en) | 1992-05-22 | 1995-04-18 | Applied Genetics Inc. | Assays for O6 -methylguanine-DNA methyltransferase |
GB9224888D0 (en) | 1992-11-27 | 1993-01-13 | Univ Singapore | Monoclonal antibody |
DK0672142T3 (da) | 1992-12-04 | 2001-06-18 | Medical Res Council | Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse |
US5753230A (en) | 1994-03-18 | 1998-05-19 | The Scripps Research Institute | Methods and compositions useful for inhibition of angiogenesis |
US5741796A (en) | 1994-05-27 | 1998-04-21 | Merck & Co., Inc. | Pyridyl and naphthyridyl compounds for inhibiting osteoclast-mediated bone resorption |
EP0767792A4 (en) | 1994-06-29 | 2002-11-20 | Smithkline Beecham Corp | VITRONECTIN RECEPTOR ANTAGONISTS |
WO1996000574A1 (en) | 1994-06-29 | 1996-01-11 | Smithkline Beecham Corporation | Vitronectin receptor antagonists |
IT1271688B (it) | 1994-08-04 | 1997-06-04 | Menarini Ricerche Sud Spa | Molecole ibride per il trattamento antitumorale loro preparazione e loro uso in composizioni farmaceutiche |
EP0777657A1 (en) | 1994-08-22 | 1997-06-11 | Smithkline Beecham Corporation | Bicyclic compounds |
WO1996026190A1 (en) | 1995-02-22 | 1996-08-29 | Smithkline Beecham Corporation | Integrin receptor antagonists |
US5780426A (en) | 1995-06-07 | 1998-07-14 | Ixsys, Incorporated | Fivemer cyclic peptide inhibitors of diseases involving αv β3 |
ATE238996T1 (de) | 1995-06-29 | 2003-05-15 | Smithkline Beecham Corp | Integrin-rezeptor-antagonisten |
DE19534177A1 (de) | 1995-09-15 | 1997-03-20 | Merck Patent Gmbh | Cyclische Adhäsionsinhibitoren |
WO1997024119A1 (en) | 1995-12-29 | 1997-07-10 | Smithkline Beecham Corporation | Vitronectin receptor antagonists |
KR19990076877A (ko) | 1995-12-29 | 1999-10-25 | 스티븐 베네티아너 | 비트로넥틴 수용체 길항제 |
IL125034A0 (en) | 1995-12-29 | 1999-01-26 | Smithkline Beecham Corp | Vitronectin receptor antagonists |
KR20000064710A (ko) | 1996-03-20 | 2000-11-06 | 제넨테크, 인코포레이티드 | 인테그린, 특히 ανβ3 인테그린에 대하여 특이 활성을갖는 3환식 화합물, 그 제조방법 및 그 제조를 위한 중간체, 의약으로서의 그 용도 및 그를 포함한 약제 조성물 |
US5925655A (en) | 1996-04-10 | 1999-07-20 | Merck & Co., Inc. | αv β3 antagonists |
JP2000508319A (ja) | 1996-04-10 | 2000-07-04 | メルク エンド カンパニー インコーポレーテッド | αvβ3拮抗薬 |
WO1997041844A1 (en) | 1996-05-09 | 1997-11-13 | Alcon Laboratories, Inc. | Combinations of angiostatic compounds |
CZ383498A3 (cs) | 1996-05-31 | 1999-05-12 | The Scripps Research Institute | Průmyslový výrobek, antagonista integrinu alfav beta3, farmaceutický přípravek s obsahem alfav beta3 antagonisty a způsob inhibice angiogeneze ve tkáni |
US6017704A (en) | 1996-06-03 | 2000-01-25 | The Johns Hopkins University School Of Medicine | Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids |
US5786146A (en) | 1996-06-03 | 1998-07-28 | The Johns Hopkins University School Of Medicine | Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids |
US5981546A (en) | 1996-08-29 | 1999-11-09 | Merck & Co., Inc. | Integrin antagonists |
CA2263999A1 (en) | 1996-08-29 | 1998-03-05 | Merck & Co., Inc. | Integrin antagonists |
JP2001501951A (ja) | 1996-10-07 | 2001-02-13 | スミスクライン・ビーチャム・コーポレイション | 骨形成刺激方法 |
AU717283B2 (en) | 1996-10-30 | 2000-03-23 | Merck & Co., Inc. | Integrin antagonists |
US5919792A (en) | 1996-10-30 | 1999-07-06 | Merck & Co., Inc. | Integrin antagonists |
EP0946165B1 (en) | 1996-10-30 | 2003-04-09 | Merck & Co., Inc. | Integrin antagonists |
AU5596298A (en) | 1996-12-09 | 1998-07-03 | Cor Therapeutics, Inc. | Integrin antagonists |
DE19653646A1 (de) | 1996-12-20 | 1998-06-25 | Hoechst Ag | Substituierte Purinderivate, Verfahren zu deren Herstellung, sie enthaltende Mittel und deren Verwendung |
DE19653647A1 (de) | 1996-12-20 | 1998-06-25 | Hoechst Ag | Vitronectin - Rezeptorantagonisten, deren Herstellung sowie deren Verwendung |
DE19653645A1 (de) | 1996-12-20 | 1998-06-25 | Hoechst Ag | Vitronectin - Rezeptorantagonisten, deren Herstellung sowie deren Verwendung |
CO4920232A1 (es) | 1997-01-08 | 2000-05-29 | Smithkline Beecham Corp | Acidos aceticos dibenzo [a,d] cicloheptano con actividad antagonista del receptor de vitronectin |
JP2001509176A (ja) | 1997-01-17 | 2001-07-10 | メルク エンド カンパニー インコーポレーテッド | インテグリンアンタゴニスト |
ES2246069T3 (es) | 1997-05-02 | 2006-02-01 | Genentech, Inc. | Procedimiento de preparacion de anticuerpos multiespecificos que tienen componentes comunes y multimericos. |
WO1999005107A1 (en) | 1997-07-25 | 1999-02-04 | Smithkline Beecham Corporation | Vitronectin receptor antagonist |
WO1999006049A1 (en) | 1997-08-04 | 1999-02-11 | Smithkline Beecham Corporation | Integrin receptor antagonists |
WO1999011626A1 (en) | 1997-09-04 | 1999-03-11 | Smithkline Beecham Corporation | Integrin receptor antagonists |
PE122699A1 (es) | 1997-09-19 | 2000-02-12 | Smithkline Beecham Corp | Antagonistas de receptores de vitronectina |
FR2768734B1 (fr) | 1997-09-24 | 2000-01-28 | Roussel Uclaf | Nouveaux composes tricycliques, leur procede de preparation et les intermediaires de ce procede, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant |
FR2768736B1 (fr) | 1997-09-24 | 2000-05-26 | Roussel Uclaf | Nouveaux composes tricycliques, leur procede de preparation et les intermediaires de ce procede, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant |
EP1017387A4 (en) | 1997-09-24 | 2004-08-18 | Smithkline Beecham Corp | VITRONEECT RECEPTOR ANTAGONIST |
BR9813214A (pt) | 1997-09-24 | 2000-08-29 | Smithkline Beecham Corp | Antagonista de receptor vitronectina |
EP1044001B1 (en) | 1997-12-17 | 2005-07-06 | Merck & Co., Inc. | Integrin receptor antagonists |
US6048861A (en) | 1997-12-17 | 2000-04-11 | Merck & Co., Inc. | Integrin receptor antagonists |
US6017926A (en) | 1997-12-17 | 2000-01-25 | Merck & Co., Inc. | Integrin receptor antagonists |
AU736026B2 (en) | 1997-12-17 | 2001-07-26 | Merck & Co., Inc. | Integrin receptor antagonists |
IL136314A0 (en) | 1997-12-17 | 2001-05-20 | Merck & Co Inc | Integrin receptor antagonists |
EA002822B1 (ru) | 1997-12-17 | 2002-10-31 | Мерк Энд Ко., Инк. | Антагонисты рецептора интегрина |
CA2319160A1 (en) | 1998-01-23 | 1999-07-29 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Monoclonal antibody anti .alpha.v-integrin and its use to inhibit .alpha.v.beta.6-integrin attachment to fibronectin |
CA2338275A1 (en) | 1998-07-29 | 2000-02-10 | Merck & Co., Inc. | Integrin receptor antagonists |
WO2000009503A1 (en) | 1998-08-13 | 2000-02-24 | Merck & Co., Inc. | Integrin receptor antagonists |
DE19842415A1 (de) * | 1998-09-16 | 2000-03-23 | Merck Patent Gmbh | Pharmazeutische Zubereitung |
US6833373B1 (en) * | 1998-12-23 | 2004-12-21 | G.D. Searle & Co. | Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
JP2002533387A (ja) * | 1998-12-23 | 2002-10-08 | ジー.ディー.サール & カンパニー | 腫瘍治療の複合療法としてインテグリン拮抗物質と一つ以上の抗腫瘍剤を使用する方法 |
TR200103431T2 (tr) | 1999-06-02 | 2002-06-21 | Merck & Co.,Inc. | Alfa V integrin reseptör antagonistleri. |
JP2004509643A (ja) | 2000-09-29 | 2004-04-02 | ザ ジョンズ ホプキンス ユニバーシティー スクール オブ メディシン | アルキル化剤を用いた化学療法による治療に対する臨床反応を予測する方法 |
AU2002219221B2 (en) * | 2001-01-09 | 2007-05-17 | Merck Patent Gmbh | Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors |
CA2478239A1 (en) * | 2002-03-04 | 2003-09-18 | Medimmune, Inc. | The prevention or treatment of cancer using integrin alphavbeta3 antagonists in combination with other agents |
JP2012509287A (ja) * | 2008-11-20 | 2012-04-19 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 癌を治療するためのインテグリンリガンドを用いる新規療法および医薬 |
-
2007
- 2007-01-18 AU AU2007207465A patent/AU2007207465B2/en not_active Ceased
- 2007-01-18 ES ES10015608.2T patent/ES2521679T3/es active Active
- 2007-01-18 BR BRPI0706540-0A patent/BRPI0706540A2/pt not_active IP Right Cessation
- 2007-01-18 WO PCT/US2007/001446 patent/WO2007084670A2/en active Application Filing
- 2007-01-18 JP JP2008551418A patent/JP2009523813A/ja active Pending
- 2007-01-18 CA CA002637387A patent/CA2637387A1/en not_active Abandoned
- 2007-01-18 EP EP07718269.9A patent/EP1973569B1/en not_active Not-in-force
- 2007-01-18 EA EA201200560A patent/EA201200560A1/ru unknown
- 2007-01-18 EA EA200801671A patent/EA016817B1/ru not_active IP Right Cessation
- 2007-01-18 US US12/161,195 patent/US20090130098A1/en not_active Abandoned
- 2007-01-18 ES ES07718269T patent/ES2425396T3/es active Active
- 2007-01-18 EP EP10015609A patent/EP2338518A1/en not_active Withdrawn
- 2007-01-18 EP EP10015608.2A patent/EP2335733B1/en not_active Not-in-force
- 2007-01-18 KR KR1020087020191A patent/KR20080089489A/ko not_active Application Discontinuation
-
2012
- 2012-11-28 JP JP2012259661A patent/JP2013049710A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EA200801671A1 (ru) | 2008-12-30 |
EP2335733B1 (en) | 2014-08-06 |
US20090130098A1 (en) | 2009-05-21 |
EP1973569A2 (en) | 2008-10-01 |
EP2335733A1 (en) | 2011-06-22 |
CA2637387A1 (en) | 2007-07-26 |
WO2007084670A3 (en) | 2007-11-22 |
ES2425396T3 (es) | 2013-10-15 |
ES2521679T3 (es) | 2014-11-13 |
WO2007084670A2 (en) | 2007-07-26 |
EA016817B1 (ru) | 2012-07-30 |
BRPI0706540A2 (pt) | 2011-03-29 |
EP1973569B1 (en) | 2013-05-22 |
EP2338518A1 (en) | 2011-06-29 |
AU2007207465A1 (en) | 2007-07-26 |
WO2007084670A8 (en) | 2008-02-28 |
AU2007207465B2 (en) | 2012-12-06 |
JP2009523813A (ja) | 2009-06-25 |
KR20080089489A (ko) | 2008-10-06 |
JP2013049710A (ja) | 2013-03-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201200560A1 (ru) | Специфическая терапия, использующая интегриновые лиганды для лечения рака | |
EA200900912A1 (ru) | Специфическая терапия и лекарственное средство на основе интегриновых лигандов для лечения рака | |
MXPA03010121A (es) | Terapia de combinacion que utiliza anticuerpos anti-receptor de factor de crecimiento epidermico y agentes anti-hormonales. | |
RU2342140C2 (ru) | Комбинированное введение индолинона с химиотерапевтическим средством при нарушениях, вызванных клеточной пролиферацией | |
WO2017079746A3 (en) | Compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer | |
EA201101651A1 (ru) | Непрерывное введение интегриновых лигандов для лечения рака | |
JP2008507530A5 (ru) | ||
TR201807411T4 (tr) | DNA-PK inhibitörleri. | |
TW200744636A (en) | Combined treatment with and composition of 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitor and anti-cancer agents | |
SG10201902664RA (en) | Combination therapy for treating cancer | |
AR074203A1 (es) | Terapia anti-angiogenesis para el tratamiento del cancer de mama. kit. uso. | |
MX2011013424A (es) | Metodo de tratamiento del cancer con antagonista dll4 y agente quimioterapeutico. | |
HK1071310A1 (en) | Combination therapy for the treatment of cancer | |
WO2015095834A3 (en) | Cancer treatments using erk1/2 and bcl-2 family inhibitors | |
DK1381384T3 (da) | Kombinationsterapi under anvendelse af anti-angiogene midler og TNFalfa | |
MX2020007130A (es) | Métodos para el tratamiento de cánceres metastásicos utilizando receptores señuelo axl. | |
RU2014137190A (ru) | Комбинации ингибитора гистон-деацетилазы и пазопаниба и их применение | |
AR049135A1 (es) | Composicion,metodo, kit y tratamiento con oxaliplatino y un inhibidor del egfr,como erlotinib | |
PH12020500096A1 (en) | Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a raf inhibitor | |
EA200801670A1 (ru) | Комбинированная противораковая терапия с перфузией изолированного органа | |
WO2010057596A3 (en) | New therapy and medicament using integrin ligands for treating cancer | |
RU2009134479A (ru) | Противоопухолевая активность ссi-779 при папиллярном раке клеток почечного эпителия | |
UA115250C2 (uk) | Фармацевтичні комбінації | |
MX2021001081A (es) | Terapia de combinacion para el tratamiento del cancer. | |
WO2014115859A3 (ja) | 分子標的併用腫瘍治療・予防薬 |